Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.22.0.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 61,880 $ 42,722 $ 42,736
Collaboration and License Agreements and Supply Agreements      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 61,880 42,722 42,736
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 11,483 11,407 11,321
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 42,780 26,075 21,458
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 4,576 5,042 8,879
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 3,041 198 1,078
BMS Agreement and the 2018 BMS Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 11,483 11,407 11,321
BMS Agreement and the 2018 BMS Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues   2,974 3,936
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 940 646 571
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Revenues 10,543 7,787 6,814
2020 Merck Master Services Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 42,780 26,075 21,458
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 35,098 18,474 14,736
2020 Merck Master Services Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,666 5,485 3,578
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 610 1,852 3,144
2020 Merck Master Services Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 4,406 264  
2019 EMD Serono Supply Agreement      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 4,576 5,042 8,879
2019 EMD Serono Supply Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue     2,266
2019 EMD Serono Supply Agreement | Contingent Payment / Milestone Earned      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,000 1,000 1,500
2019 EMD Serono Supply Agreement | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 851 1,316 2,890
2019 EMD Serono Supply Agreement | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,725 2,726 2,223
Supply Agreement | Vaxcyte, Inc.      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 3,041 198 1,078
Supply Agreement | Vaxcyte, Inc. | Research and Development Services      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 1,131 184  
Supply Agreement | Vaxcyte, Inc. | Materials Supply      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 1,910 $ 14 $ 1,078